Literature DB >> 20442456

Medical and societal consequences of late presentation.

Santiago Moreno1, Amanda Mocroft, Antonella d'Arminio Monforte.   

Abstract

Patients presenting late with HIV infection are at a higher risk of clinical events, are difficult to treat and have a higher mortality compared with those who present earlier. Indeed, being diagnosed too late for effective treatment has been shown to be a common scenario leading to death. The increased risk for opportunistic diseases and increased mortality are associated with low CD4(+) T-cell counts. In addition to the detrimental effect on the health of the individual, late presentation also creates a significant societal burden because it is associated with increased risk of HIV transmission and increased resource use. All of these factors highlight the benefit of earlier testing, diagnosis and treatment of HIV.

Entities:  

Mesh:

Year:  2010        PMID: 20442456     DOI: 10.3851/IMP1523

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  20 in total

1.  Estimating minimum adult HIV prevalence: a cross-sectional study to assess the characteristics of people living with HIV in Italy.

Authors:  Laura Camoni; Mariangela Raimondo; Maria Dorrucci; Vincenza Regine; Maria Cristina Salfa; Barbara Suligoi
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01-06       Impact factor: 2.205

2.  Correlates of Late Presentation to HIV care in a South Indian Cohort.

Authors:  Satish Rao; Satheesh Av; Bhaskaran Unnikrishnan; Deepak Madi; Avinash K Shetty
Journal:  Am J Trop Med Hyg       Date:  2018-11       Impact factor: 2.345

3.  Are participants in a street-based HIV testing program able to perform their own rapid test and interpret the results?

Authors:  Luis de la Fuente; María Elena Rosales-Statkus; Juan Hoyos; José Pulido; Sara Santos; María José Bravo; Gregorio Barrio; Sonia Fernández-Balbuena; María José Belza
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

4.  Expanding HIV testing efforts in concentrated epidemic settings: a population-based survey from rural Vietnam.

Authors:  Anastasia Pharris; Thi Kim Chuc Nguyen; Carol Tishelman; Ruairí Brugha; Phuong Hoa Nguyen; Anna Thorson
Journal:  PLoS One       Date:  2011-01-11       Impact factor: 3.240

5.  Reduced Central Memory CD4+ T Cells and Increased T-Cell Activation Characterise Treatment-Naive Patients Newly Diagnosed at Late Stage of HIV Infection.

Authors:  Francesca Bai; Camilla Tincati; Esther Merlini; Carlotta Pacioni; Elisabetta Sinigaglia; Giovanni Carpani; Antonella d'Arminio Monforte; Giulia Marchetti
Journal:  AIDS Res Treat       Date:  2011-10-27

6.  Testing initiatives increase rates of HIV diagnosis in primary care and community settings: an observational single-centre cohort study.

Authors:  Prini Mahendran; Suneeta Soni; Stephanie Goubet; Emma Saunsbury; Jonathan Roberts; Martin Fisher
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

7.  Substance Abuse Treatment, HIV/AIDS, and the Continuum of Response for People Who Inject Drugs.

Authors:  Thomas F Kresina; Robert Lubran; H Westley Clark; Laura W Cheever
Journal:  Adv Prev Med       Date:  2012-11-29

8.  Never tested for HIV in Latin-American migrants and Spaniards: prevalence and perceived barriers.

Authors:  Juan Hoyos; Sonia Fernández-Balbuena; Luis de la Fuente; Luis Sordo; Mónica Ruiz; Gregorio Barrio; María José Belza
Journal:  J Int AIDS Soc       Date:  2013-05-09       Impact factor: 5.396

9.  Late presenters among persons with a new HIV diagnosis in Italy, 2010-2011.

Authors:  Laura Camoni; Mariangela Raimondo; Vincenza Regine; Maria Cristina Salfa; Barbara Suligoi
Journal:  BMC Public Health       Date:  2013-03-27       Impact factor: 3.295

10.  Widening the Access to HIV Testing: The Contribution of Three In-Pharmacy Testing Programmes in Spain.

Authors:  Sonia Fernández-Balbuena; María José Belza; Daniel Zulaica; Jose Luis Martinez; Henar Marcos; Benet Rifá; Arantxa Arrillaga; Luis de la Fuente; Juan Hoyos
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.